Multizonal observational study conducted by clinical practitioners on Repatha® use in patients with hyperlipidemia (ZERBINI): Colombian results.

[1]  G. Mancini,et al.  Real-World Insights Into Evolocumab Use in Patients With Hyperlipidemia: Canadian Analysis From the ZERBINI Study , 2022, CJC open.

[2]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[3]  V. Barrios,et al.  First national registry on the effectiveness and safety of evolocumab in clinical practice in patients attended in cardiology in Spain. The RETOSS-CARDIO study. , 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[4]  A. Román-González,et al.  Dyslipidaemias and their treatment in high complexity centres in Colombia. , 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[5]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[6]  R. Giugliano,et al.  Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. , 2019, Journal of the American College of Cardiology.

[7]  G. Lundberg,et al.  Lipids in Women: Management in Cardiovascular Disease Prevention and Special Subgroups , 2019, Current Cardiovascular Risk Reports.

[8]  Kamlesh Khunti,et al.  Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.

[9]  D. Zodda,et al.  Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs , 2018, Pharmacy.

[10]  B. Coll,et al.  Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. , 2017, Journal of clinical lipidology.

[11]  J. Kleijnen,et al.  Systematic Review and Network Meta‐Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia , 2017, Journal of the American Heart Association.

[12]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[13]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[14]  A. Asadi,et al.  0097 : Influence of dyslipidemia on clinical characteristics in heart failure patients. Series of 583 cases , 2015 .

[15]  V. Bittner,et al.  Lipid-lowering therapy in patients 75 years and older: clinical priority or superfluous therapy? , 2014, Progress in cardiovascular diseases.

[16]  D. Levy,et al.  Relations of Lipid Concentrations to Heart Failure Incidence: The Framingham Heart Study , 2009, Circulation.